Krahasoni metodat

	Vlerësimi Prospektiv i Testit të Skriningut	Vlerësimi i Testeve dhe Programve Shqyrtuese
Fusha	Epidemiologji	Epidemiologji
Familja	Process / pipeline	Process / pipeline
Viti i origjinës	1980s–2000s (STARD 2003, updated 2015)	1968 (Wilson-Jungner principles); statistical framework developed 1970s–2000s
Krijuesi	Formalized through diagnostic accuracy methodology (Sackett, Haynes, Tugwell; STARD initiative)	Wilson & Jungner (WHO criteria, 1968); foundational work by Pepe, Altman, and others in statistical test evaluation
Lloji	Prospective observational study design	Observational diagnostic / epidemiological evaluation design
Burimi themelues	Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., et al. (2015). STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. BMJ, 351, h5527.	Wilson, J. M. G., & Jungner, G. (1968). Principles and Practice of Screening for Disease. World Health Organization. Public Health Papers No. 34.
Emërtime të tjera	prospective diagnostic accuracy study, prospective test performance study, forward-looking screening validation, prospective DTA study	screening study, screening performance evaluation, screening accuracy assessment, STE
Të lidhura	6	6
Përmbledhja	A prospective screening test evaluation enrolls participants before the outcome is known, applies the screening test and the reference standard in temporal sequence, and measures how accurately the test identifies individuals with or without the target condition. This forward-looking design minimizes workup bias and spectrum bias, producing estimates of sensitivity, specificity, and predictive values that are more generalizable to real clinical or public-health screening contexts than retrospective alternatives.	Screening test evaluation is a systematic epidemiological approach for assessing whether a test or program can accurately and cost-effectively identify individuals with a condition before symptoms appear. It quantifies diagnostic performance metrics — sensitivity, specificity, predictive values, and the ROC curve — and evaluates whether a screening program meets established public health criteria for adoption and harm-benefit balance.